Cytek Holds Guidance Midpoint as Gross Margin Jumps 590 bps, Revenue Up 2%
CTKB sits 78% above its 52-week low of $3.31.
Summary
Cytek reported Q3 2026 revenue of $53.2 million, up 2% year over year, with GAAP gross margin expanding 590 basis points to 59% — the best third-quarter margin since 2023. Recurring service and reagent revenue reached $19.1 million and now represents 36% of trailing-12-month revenue, up from 33% a year ago, while the installed base grew by 140 units to 4,073 instruments. The top line is modest, but the margin gain and mix shift toward recurring revenue are the real story. Profitability remains thin: net loss widened to $6.1 million from $5.5 million, and adjusted EBITDA fell to $0.7 million from $2.5 million, with G&A up 14% on litigation costs tied to the Beckman Coulter patent case. Management kept the midpoint of full-year 2026 revenue guidance and narrowed the range to $208 million to $211 million, implying a stronger fourth quarter to hit the low end. The balance sheet is a cushion — $256.3 million in cash and marketable securities against a small market cap — but the legal overhang from the $56.11 million jury award remains the swing factor.
At the time of this announcement, CTKB was trading at $5.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $764.3M. The 52-week trading range was $3.31 to $6.34. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.